Labsystems Diagnostics Oy, Finland has been a forerunner in innovative diagnostic research and development for the last 40 years. The company develops, manufactures and markets high quality enzyme immunoassays (EIA, FEIA and MIFA), molecular assays (MDx) and Point-of-Care (POC) tests.

As an established European company, Labsystems Diagnostics has committed itself to developing high quality diagnostics products for use in clinical and research laboratories, for consumer use and as OEM products. The company strongly invests in research and development, in its highly qualified personnel and state-of-the-art production. A highly rigorous quality system and CE-marked products ensure sustainable quality of the products. These assets combined with efficient customer support, long term customer satisfaction and a solid reputation ensure success.

Within 40 years of experience, throughout different ownerships, Labsystems Diagnostics has been a key pioneer to achieve many milestones. Labsystems Diagnostics Oy is well known for its world’s first revolutionary microplate ELISA reader - The Multiskan, which was developed and launched in the global markets back in 1978. The company was one of the first in the world to develop EIA tests on microplate format, as well as to create a peptide based HIV assay.

The first fluorometric PKU test for Newborn Screening on microplate was developed by the company. In the Point-of-Care field discipline, the company was the first to launch Troponin I test, patented Celiac test and Chlamydia pneumoniae IgM test. The fully automated high throughput system and LC-MS tests for Newborn Screening are the most recent milestones.

Newborn Screening | Point of Care | Immunology | Molecular Diagnostics | HPLC & LC-MS/MS